Drugs / BAY3018250
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06619483 | Oct 2024 → Jan 2025 | venous thromboembolism | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT06562985 | Sep 2024 → Jan 2025 | venous thromboembolism | Bayer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06149520 | Jan 2024 → Oct 2025 | venous thromboembolism | Bayer | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-02-20 | Bayer | Regulatory Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis bayer.com ↗
Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-02-20 | Bayer | Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis bayer.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY3018250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06562985 ↗ |
| Route | Intravenous | “healthy Japanese men after receiving different doses of BAY3018250 as an infusion into a vein.” NCT06562985 ↗ |